Navigation Links
Modifying an anti-cancer drug makes it more specific
Date:12/3/2007

Imatinib (marketed as Gleevec in the US and Glivec in Europe and Australia) is used to treat various cancers, including chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). It can be used to treat these two distinct types of cancer because they are caused by related proteins tyrosine kinases. However, this lack of specificity for a single protein means that imatinib can also inhibit tyrosine kinases that mediate normal bodily functions and it has been reported that in some patients this causes a toxic effect on the heart. To address some of these problems, Ariel Fernndez and colleagues at Rice University, Houston, have engineered a modified form of imatinib (known as WBZ_4) that inhibited the tyrosine kinase behind GISTs (c-KIT) as effectively as imatinib did, and that neither inhibited the tyrosine kinase behind CML (BCR-Abl) nor had toxic effects on the heart when it was administered to mice. Importantly, WBZ_4 was as effective as imatinib at reducing tumor volume and weight in a mouse model of GISTs. As noted by George Demetri from the Dana-Farber Cancer Institute, Boston, in the accompanying commentary, this study gives hope that in the future it might be possible to construct ever-better agents that can be combined safely and effectively to manage, and eventually cure, many forms of human cancer.


'/>"/>

Contact: Karen Honey
press_releases@the-jci.org
215-573-1850
Journal of Clinical Investigation
Source:Eurekalert

Page: 1

Related biology technology :

1. Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents
2. Southern Research Institute Licenses Anti-Cancer Drug Compound to Virium Pharmaceuticals
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Web Portal Makes Organ Donation Easy
5. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
6. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
7. Argonne researcher studies what makes quantum dots blink
8. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
9. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
10. BioSpecifics to Present at the 9th Annual Healthcare Conference of Acumen Bio Fin Rodman Renshaw LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 4, 2015 Lancée ... Paris en décembre 2011, l,étude collaborative ... », qui compare   l es microsphères ... sorafénib dans le carcinome hépatocellulaire avancé, a recruté ... foie avancé   ; les résultats sont attendus ...
(Date:3/3/2015)... 2015 NASA astronaut Scott Kelly , who ... spend a year living and working on the International Space ... to 7 a.m. EDT Monday, March 9. Kelly ... completes the final weeks of his training. The interviews will ... Television highlighting his mission training and previous spaceflights. ...
(Date:3/3/2015)... SAN DIEGO , March 3, 2015  Neurocrine ... that Kevin Gorman , President and Chief Executive ... Barclays Global Healthcare Conference in Miami.   ... at 10:15am ET (7:15am PT).  The presentation will be ... at http://www.neurocrine.com .   Listeners are ...
(Date:3/3/2015)... March 03, 2015 Crown Bioscience, Inc., ... has launched a new Life Science division specializing in ... research. , The first products released include in ... and soon to be released in vivo grade monoclonal ... to expand their life science portfolio with additional antibody ...
Breaking Biology Technology:Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6NASA Astronaut Scott Kelly Available for Interviews before One-Year Space Station Mission 2Crown Bioscience Launches Life Science Product Catalog 2
... Basis, Proprietary MicroRNAs for Research Applications ... has Access to a Full Range of ... on These MicroRNAs, REHOVOT, Israel and JERSEY CITY, ... ), a leading,developer of microRNA-based diagnostics and therapeutics, announced ...
... Alfacell Corporation,(Nasdaq: ACEL ) today announced that Kuslima ... retire from the company on,or before March 31, 2009. ... Shogen and Alfacell has been terminated., The termination ... reduce payments from the Company to Ms. Shogen by ...
... to Date Examined 175,000 Teenage Girls and Adult ... before motherhood,more than doubled in six years among ... study published in the May issue of Diabetes ... looked exclusively at gestational diabetes,(diabetes that develops during ...
Cached Biology Technology:Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate 2Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate 3Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate 4Alfacell Announces Retirement of Chief Executive Officer 2Alfacell Announces Retirement of Chief Executive Officer 3Alfacell Announces Retirement of Chief Executive Officer 4Kaiser Permanente Study Finds Diabetes Doubling Before Motherhood 2Kaiser Permanente Study Finds Diabetes Doubling Before Motherhood 3Kaiser Permanente Study Finds Diabetes Doubling Before Motherhood 4
(Date:2/5/2015)... 30, 2015  It is gratifying to see that ... for genomic science as a means to better understand ... treatment.  I was honored to participate in today,s White ... program. Since the 1980s my teams ... the first sequenced genome of a free living organism, ...
(Date:1/22/2015)... CHICAGO , Jan. 9, 2015 Valid S.A. ("Company") ... the market in general the State of Washington,s ... contract for a new enrollment and central issuance system for ... The project planning and development will start ...
(Date:1/22/2015)... Showcase, Hall E -   EyeLock Inc. , a market ... showcase its EyeLock ID technology integrated in a 3D printed ... Oak Ridge National Laboratory (ORNL) at the 2015 ... technology is being used to validate the driver and authorize ...
Breaking Biology News(10 mins):J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Valid USA Signs Contract For Washington Driver's License Issuance 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3
... SALT LAKE CITY People who are at risk ... cancer may soon have a better chance at surviving or ... by the Intermountain Clinical Genetics Institute at LDS Hospital. ... to develop a reliable and cost-effective way to identify patients ...
... DC -- A team of researchers at the Department ... exact, single gene that controls ethanol production capacity in ... in developing biomass crops that produce higher concentrations of ... of Energy relies on the scientific discoveries of its ...
... of mammary gland biology are essential in the fight ... as an Experimental Model , this organ represents an ... processes that occur throughout the body. The branching morphogenesis ... pregnancy, for example, recapitulate steps that occur in many ...
Cached Biology News:New process that may save lives of cancer patients is effective and significantly less costly 2New process that may save lives of cancer patients is effective and significantly less costly 3Single, key gene discovery could streamline production of biofuels 2
Rabbit polyclonal antibody to NMDA NR2B [Tyr1336]...
... with the DeCypher Engine accelerator cards to speed ... searches like these from your desktop: BLAST ... 6 days Align BAC-sized queries (~250 ... analysis to compare 100,000 sequences to PFAM in ...
... tetrasodium bromide), 50mg/vial. MTT is a pale ... cells to yield a dark blue formazan ... even freshly dead cells do not cleave ... a component of Chemicons MTT assay kit, ...
Mouse monoclonal antibody to FMN2 - formin 2...
Biology Products: